ClinicalTrials.gg
CompletedNCT02927353DMB-3113-1Updated Aug 22, 2017

A Phase 1 Pharmacokinetic Bioequivalence Study of DMB-3113 and Adalimumab in Healthy Japanese Adult Male Subjects

A Phase 1 interventional study of DMB-3113 and Adalimumab in Healthy Volunteer, sponsored by Meiji Seika Pharma Co., Ltd.. Completed at 1 site in Japan. Open to male participants aged 20 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-08-22.

Sponsored by Meiji Seika Pharma Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
20 Years to 39 Years
Sex
Male
01

Study summary

To determine the pharmacokinetic bioequivalence of DMB-3113 and adalimumab and to confirm the safety of the study drug in healthy Japanese adult male subjects

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Bioequivalence, Biosimilarity, Pharmacokinetics, adalimumab
03

In context

Lead sponsor

Meiji Seika Pharma Co., Ltd. is the lead sponsor of 10 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 39 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy Japanese male adults;
  2. The (BMI) of the subjects must be from 17.6 to 26.4 kg/m2 at the time of the screening test;and
  3. Subjects must take a screening test within the 4 weeks before the date of administration of the study drug; subjects must take a screening test before the date of administration of the study drug and exhibit no clinically abnormal findings in the judgment of the investigator or any of the subinvestigators

Exclusion criteria

Exclusion Criteria:

  1. Concurrent or history of potentially fatal infections such as opportunistic infections, including sepsis, pneumonia, and fungal infection;
  2. Individuals with history of tuberculosis or diagnosed with tuberculosis by interview, chest X-ray examination, or interferon-gamma release assay;
  3. Concurrent or history of demyelinating disease (multiple sclerosis, etc.);
  4. Concurrent or history of congestive cardiac failure;
  5. Concurrent or history of allergic symptoms such as asthma bronchial, drug-induced rash, and urticaria, which, in the judgment of the investigator or any of the subinvestigators, may affect participation in this clinical study; or
  6. Concurrent or history of cardiac, hepatic, renal, gastrointestinal, respiratory, and/or hematological function disorders, which, in the judgment of the investigator or any of the subinvestigators, may affect participation in this clinical study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    DMB-3113

    adalimumab biosimilar

    Drug: DMB-3113

  • Active comparator
    adalimumab

    adalimumab

    Drug: Adalimumab

Interventions

  • DrugDMB-3113

    subcutaneously injected in a single dose of 40 mg.

  • subcutaneously injected in a single dose of 40 mg.

06

What researchers measure

Primary outcomes

  1. Area under the serum concentration-time curve (AUC) from 0 to final sampling time point

    Time frame: Day 1 to Day 71

  2. AUC from 0 to infinity

    Time frame: Day 1 to Day 71

  3. Maximum serum concentration (Cmax)

    Time frame: Day 1 to Day 71

Secondary outcomes

  1. AUC from 0 to the last measurable concentration

    Time frame: Day 1 to Day 71

  2. Time to reach the peak concentration (tmax)

    Time frame: Day 1 to Day 71

  3. Mean residence time (MRT) from 0 to final sampling time point

    Time frame: Day 1 to Day 71

  4. MRT from 0 to infinity

    Time frame: Day 1 to Day 71

  5. Elimination rate constant (kel)

    Time frame: Day 1 to Day 71

  6. Elimination half life (t1/2)

    Time frame: Day 1 to Day 71

  7. Observed clearance (CL/F)

    Time frame: Day 1 to Day 71

  8. Observed volume of distribution (V/F)

    Time frame: Day 1 to Day 71

  9. Incidence of adverse events

    Time frame: Day 1 to Day 71

07

Study locations

1 site
  • Fukuoka, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2016, a primary completion of Jan 2017 and a completion of Jan 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2016
First posted
Oct 7, 2016
Start
Aug 2016
Primary completionActual
Jan 17, 2017
CompletionActual
Jan 17, 2017
Last update
Aug 22, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02927353
Lead sponsor
Meiji Seika Pharma Co., Ltd.
Responsible party
Sponsor
First posted
Oct 7, 2016
Start date
Aug 2016
Primary completion
Jan 17, 2017
Completion
Jan 17, 2017
Last update
Aug 22, 2017

Study contacts

Hideki Fushimi, Manager
study director · Meiji Seika Pharma Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion